16 September 2026 editorial review · Trial
MetMod-T1D: AMX0035 and insulin sensitivity: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: New 60-person Phase 2 protocol testing AMX0035 (sodium phenylbutyrate + taurursodiol) with clamp insulin sensitivity primary; research, not an available T1D treatment.
Registry: NCT07699380; RECRUITING; updated 2026-09-15; enrollment 60 (ESTIMATED); results not posted.
Endpoint comparison: Change in whole-body insulin sensitivity (M-value) measured by hyperinsulinemic-euglycemic clamp (Baseline, 24 weeks).
Sources for this record: METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D) (NCT07699380) (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.